Hinova Pharmaceuticals (SH:688302)2025-01-17 09:50Financial Performance - The company expects a net loss attributable to shareholders of the parent company for 2024 to be between -220 million and -180 million CNY, a reduction in loss of 74.16 million to 114.16 million CNY compared to the previous year, representing a year-on-year decrease in loss of 25.51% to 38.81%[4] - The expected net loss attributable to shareholders after deducting non-recurring gains and losses is projected to be between -240 million and -195 million CNY, a reduction in loss of 85.03 million to 130.03 million CNY compared to the previous year, representing a year-on-year decrease in loss of 26.16% to 40.01%[4] Revenue and Sales - The company has not yet obtained commercial sales approval for any drugs, resulting in an estimated revenue from the sale of materials and R&D intermediates of approximately 350,000 to 400,000 CNY, with no revenue in the same period last year[8] - The company is advancing the commercialization team and sales strategy for the drug HC-1119, leading to an increase in sales expenses during the reporting period[8] Research and Development - The estimated R&D expenses for 2024 are projected to be between 158 million and 188 million CNY, a decrease of 36.36% to 24.28% compared to the previous year's R&D expenses of 248.27 million CNY[8] Expenses and Financial Management - The company has experienced a reduction in share-based payment expenses due to the expiration of stock incentives and a decrease in investment income from financial management[8] Caution for Investors - The company emphasizes that the performance forecast is based on preliminary calculations and has not been audited by registered accountants, highlighting the importance of caution for investors[10][11]